About Likarda
Likarda is a Healthcare company based in Kansas City (United States) founded in 2012. Developer of 3D cell cultures for regenerative medicine. Likarda has raised $4 million across 2 funding rounds from investors including HHS. The company has 8 employees. Likarda offers products and services including Core-Shell Spherification, Microencapsulation, and ViscoBeads. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is LIKARDA, LLC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Likarda is creating 3D cell culturesminiaturized organs from their proprietary cell culture systems which will have potential applications in drug discovery, development, cell-based transplantation, and regenerative medicine. The company offers integrated early-stage discovery research along with consultative and analytical services. The company has created Kanslet, a reaggregated islet capable of producing insulin (from a donor pancreas) which can be transplanted into dogs and cats for treating diabetes. Kanslets can also be used for secondary drug testing and multiple studies have been published already in support of the technology.
- Headquarters Kansas City, United States
- Employees 8
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website likarda.com
- Social LinkedIn X Facebook Instagram
- Legal Name Likarda, Llc
- Total Equity Funding$4M (USD)
in 2 rounds
- Latest Funding Round$256.34K (USD), Grant
Sep 2021
- Investors
- Employee Count8
Products & Services of Likarda
Likarda offers a comprehensive portfolio of products and services, including Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Method for encapsulating cells to optimize therapy delivery and efficacy.
Process to protect cell therapies from immune systems using hydrogels.
Customizable beads for targeted cell therapy administration.
Funding Insights of Likarda
Likarda has successfully raised a total of $4M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $256.34 thousand completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 2
- Last Round Grant — $256,338
- First Round $4M
(Aug 2017)
- Investors Count 1
All 2 funding rounds of Likarda with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $256,338 | Grant | – | – | |
| Aug 2017 | $4M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Likarda
Likarda has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Likarda
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Likarda
7 people are tracked at Likarda (5 in leadership, 1 in board & advisors, 1 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Stephen Harrington | Director Of Hydrogel And Cell Formulation | Leadership |
Shelly Adams | Chief Commercial Officer | Leadership |
Joe Suarez | CFO | Leadership |
Francis Karanu | Director, Cell Therapy & R&d | Leadership |
Stella Vnook | CEO | Leadership |
Andrea Dennis-LaVigne | Board Member | Board & advisors |
Janette Williams | Lab Manager and Research Scientist | Team |
Complete people profiles for Likarda
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Likarda
3 dated milestones of Likarda across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Likarda is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Grant, of $256K.
Competitors of Likarda
Likarda has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Likarda
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Likarda
The website of Likarda (likarda.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 14.2% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Likarda (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Likarda
Complete news archive for Likarda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Likarda
Likarda was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Likarda is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Likarda is a funded company, having raised a total of $4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Aug 2017.
Likarda has 8 employees.
Likarda is creating 3D cell culturesminiaturized organs from their proprietary cell culture systems which will have potential applications in drug discovery, development, cell-based transplantation, and regenerative medicine. The company offers integrated early-stage discovery research along with consultative and analytical services. The company has created Kanslet, a reaggregated islet capable of producing insulin (from a donor pancreas) which can be transplanted into dogs and cats for treating diabetes. Kanslets can also be used for secondary drug testing and multiple studies have been published already in support of the technology.
Likarda's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Likarda offers Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Likarda has 1 investor. Key investors include HHS.
Likarda operates through Likarda, Llc.